R&D

News

Novartis axes asthma drug fevipiprant after more trial woes

It’s nearly always bad news when pharma companies provide an “update” about a trial – and the statement today from Novartis about its asthma drug fevipiprant must make bleak reading for all

News

Pharma prepares for Brexit as Tories win election majority

Boris Johnson’s Conservatives have won the UK’s general election with a large majority, leaving the industry preparing for Brexit and the possibility of a more US-influenced pharma market.<

News

GSK leanest with R&D spend in big pharma - but gets bang for...

GlaxoSmithKline’s CEO Emma Walmsley has made great play of her company’s new approach to R&D under the leadership of its guru Hal Barron.

News

Sanofi axes diabetes R&D, focuses on 'transformative' therap...

Take a look at Sanofi’s balance sheet and it’s obvious which way the wind is blowing – sales in its once mighty diabetes franchise are sliding, while newer medicines such as its eczema and

News

Sanofi snaps up Synthorx for $2.5bn, eyeing cancer immunothe...

Sanofi has agreed to buy cancer drugs firm Synthorx for around $2.5 billion, aiming to strengthen its immune-oncology drug pipeline and creating the possibility of new combination therapies

News

Illustration of a nerve cell on a colored background with light effects

Neurocrine and Xenon agree $1.75bn epilepsy R&D tie-up

Two biotechs, Neurocrine Biosciences and Xenon, have announced a licence and collaboration agreement to develop first-in-class treatments for epilepsy in a deal worth up to $1.75 billion.

Novartis axes asthma drug fevipiprant after more trial woes

Pharma prepares for Brexit as Tories win election majority

GSK leanest with R&D spend in big pharma - but gets bang for...

Sanofi axes diabetes R&D, focuses on 'transformative' therap...

Sanofi snaps up Synthorx for $2.5bn, eyeing cancer immunothe...

Neurocrine and Xenon agree $1.75bn epilepsy R&D tie-up

Delivering the right behavioural ingredients for the moment,...

How to meet your physicians where they are online

R&amp;D

Editor's Picks

R&D